AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2016
Mar 14, 2016
35334_dirs_2016-03-14_6857653a-d857-42fa-966c-24832ef49e10.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2016-03-11
Reporting Person: Equels Thomas K. (Director, CEO,Pres,Exec Vice Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-03-11 | Common Stock | P | 30000 | $0.1564 | Acquired | 30000 | Direct |
| 2016-03-11 | Common Stock | P | 10000 | $0.1618 | Acquired | 10000 | Direct |
More from AIM ImmunoTech Inc.
Share Issue/Capital Change
2026
Jun 11
Governance Information
2026
Jun 10
Capital/Financing Update
2026
Jun 10
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21
Share Issue/Capital Change
2026
May 19
Capital/Financing Update
2026
May 19
Interim / Quarterly Report
2026
May 15